Title : Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study.

Pub. Date : 2019 Feb

PMID : 30178545






7 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study. Metformin growth differentiation factor 15 Homo sapiens
2 Produced as a tissue defence response to hypoxia and inflammation, growth differentiation factor-15 (GDF-15) is elevated in people receiving metformin treatment. Metformin growth differentiation factor 15 Homo sapiens
3 Produced as a tissue defence response to hypoxia and inflammation, growth differentiation factor-15 (GDF-15) is elevated in people receiving metformin treatment. Metformin growth differentiation factor 15 Homo sapiens
4 To gain insight into the relationship of GDF-15 with metformin and major cardiovascular risk factors, we analysed the data from the SUMMIT cohort (n = 1438), a four-centre, nested, case-control study aimed at verifying whether biomarkers of atherosclerosis differ according to the presence of type 2 diabetes and cardiovascular disease. Metformin growth differentiation factor 15 Homo sapiens
5 In participants with diabetes, metformin treatment was associated with a 40% rise in GDF-15 level, which was independent of the other major factors, and largely explained their elevated GDF-15 levels. Metformin growth differentiation factor 15 Homo sapiens
6 In participants with diabetes, metformin treatment was associated with a 40% rise in GDF-15 level, which was independent of the other major factors, and largely explained their elevated GDF-15 levels. Metformin growth differentiation factor 15 Homo sapiens
7 The relatively high GDF-15 bioavailability might partly explain the protective cardiovascular effects of metformin. Metformin growth differentiation factor 15 Homo sapiens